SecBot SecBot
DEFA14A ·Filed Nov 9, 2026

HRTX

HERON THERAPEUTICS, INC. /DE/
NEUTRAL
Impact 6/10
Horizonmonths Processed7d 10h ago SEC0001193125-26-453822
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the proxy statement filing for the stockholder vote date and any potential competing bids or regulatory hurdles. The earn-out milestones for ZYNRELEF ($65M and $95M in net sales in 2028) are key value drivers for the contingent consideration. Heron's post-closing strategy as a cash-rich public company with NOLs will determine its next corporate action.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

HRTX drug pipeline →

APONVIE

● Neutral Named in this DEFA14A
Impact
Phase
Approved
Time to market
Already approved and commercially available since March 2023.
Next catalyst
None dated

What to watchAPONVIE is now part of the CorMedix asset acquisition announced November 9, 2026. The deal is expected to close in Q1 2027. For Heron shareholders, the stock's value will increasingly reflect the CRMD shares and NOLs Heron retains post-close rather than APONVIE's standalone commercial trajectory. For CorMedix, APONVIE adds a growing hospital antiemetic to its institutional portfolio.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.3741
T+0 close · Nov 9, 2026 · via day close
Latest settled
−3.96%
T+1 · $0.3593 · next T+5 in 3h
Vs SPY
−5.28%
α at T+1
Latest observation
−21.62%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $0.3741entry
  2. T+1 · 6d ago −3.96%α −5.28% · $0.3593
  3. T+4 · todayOpen
  4. T+5 · in 3h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Heron Therapeutics filed a DEFA14A (definitive additional proxy soliciting materials) announcing that CorMedix will acquire substantially all of Heron's assets, including its four commercial-stage products (ZYNRELEF, APONVIE, CINVANTI, SUSTOL), for upfront consideration of $145 million in cash and 14,583,333 shares of CorMedix common stock (valued at approximately $77.6 million based on CRMD's November 6, 2026 closing price of $5.32), plus potential earn-out payments of up to $55 million and royalties. The transaction is expected to close in Q1 2027, subject to Heron stockholder approval, regulatory clearance, and other customary conditions. Stockholders representing approximately 22% of Heron's outstanding common stock have agreed to vote in favor.

Key Financial Metrics

Vote
merger approval

Key Facts

  • CorMedix to acquire substantially all of Heron's assets for $145 million cash plus 14,583,333 shares of CorMedix common stock (aggregate upfront value approx. $222.6 million based on CRMD closing price of $5.32 on Nov 6, 2026)
  • Heron eligible for up to $55 million in earn-out payments: $25 million if ZYNRELEF net sales >= $65 million in 2028, plus $30 million if ZYNRELEF net sales >= $95 million in 2028
  • Heron to receive a 5% royalty on combined annual net sales above $25 million in each of years 2027-2029 of CINVANTI, SUSTOL and products under Heron's multi-product Development and License Agreement
  • Hercules Capital credit facility expected to be repaid at closing from upfront cash consideration
  • Rubric Capital Management has agreed to exchange its convertible debt for shares of CorMedix common stock received by Heron in four quarterly tranches post-closing
  • Heron will have the right to name one new member to the CorMedix Board so long as it holds at least 10% of outstanding CorMedix shares
  • Stockolders representing approximately 22% of Heron's outstanding common stock, including Rubric, have agreed to vote in favor
  • Transaction expected to close in Q1 2027, subject to Heron stockholder approval, regulatory clearance, and other customary conditions; not subject to any financing contingency
  • Heron will remain a publicly traded company after closing and intends to evaluate strategic transactions for use of proceeds, including potential acquisition of businesses or assets, royalty streams, or product candidates
  • Heron will retain material assets including CorMedix common stock, rights to earn-out and royalty payments, significant NOLs, and cash on hand

Financial Impact

Upfront consideration of $145 million cash plus 14,583,333 shares of CorMedix common stock (approx. $77.6 million based on CRMD $5.32 close on Nov 6, 2026), aggregate approx. $222.6 million; plus up to $55 million in earn-out payments and a 5% royalty on certain net sales above $25 million annually in 2027-2029

revenuedebtdilution

Risk Factors

  • Failure to obtain Heron stockholder approval or required regulatory clearances could terminate the deal
  • Heron's stock price may decline if the transaction is not completed
  • Value of CorMedix common stock received as consideration may decline, and Heron may be unable to sell or monetize shares when expected
  • Heron may not identify or complete a suitable acquisition or investment after closing, and its ability to use NOLs may be limited
  • Heron may not regain or maintain compliance with Nasdaq continued listing requirements after closing
  • Potential litigation relating to the proposed transaction

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-453822
Document: 0001193125-26-453822-index-headers.html0001193125-26-453822
Document: 0001193125-26-453822-index.html0001193125-26-453822
Document: 0001193125-26-453822.txt0001193125-26-453822

Track record

15 reports on HRTX

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +58.33% at T+20 after the May 11, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 9, 20267d ago DEFA14A Neutral 6/10 Viewing Entry $0.3741 Now $0.2800 −25.15% settles Feb 8
  2. Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  3. Nov 9, 20267d ago 8-K Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  4. Nov 9, 20267d ago 8-K Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  5. Nov 9, 20267d ago Press Release Mixed 7/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  6. Aug 10, 202614w ago 8-K Bearish 7/10 No price data
  7. Aug 10, 202614w ago Press Release Bearish 7/10 Entry $0.3350 to $0.2847 Now $0.2800 +16.42% ▲ +15.01% +12.60% vs SPY
  8. Jun 25, 202620w ago 8-K Bearish 7/10 Entry $0.4300 to $0.2700 Now $0.2800 +34.88% ▲ +37.21% +43.31% vs SPY
  9. Jun 2, 202623w ago 8-K Bearish 7/10 Entry $0.4500 to $0.3321 Now $0.2800 +37.78% ▲ +26.20% +28.70% vs SPY
  10. May 11, 202627w ago 8-K Bearish 6/10 No price data
Showing 10 of 15

US Market Status

Market Closed · Opens in 5h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026